Feature | May 14, 2013

Study Compares Multidisciplinary Convergent Procedure to Endocardial Catheter Ablation to Treat AF

The CONVERGE IDE clinical trial may set a new standard of care in AF ablation

The EPi-Sense-AF Guided Coagulation System.

May 14, 2013 — nContact Inc. said it received conditional approval for an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in the CONVERGE trial, a multicenter, prospective, randomized study evaluating patients with symptomatic persistent atrial fibrillation (AF). AF is the most common cardiac arrhythmia, a condition that disrupts the ability of the atria (upper chambers of the heart) to beat regularly and pump blood efficiently. The CONVERGE study, designed to investigate the  epicardial/endocardial Convergent Procedure, combines the cardiac ablation expertise, techniques, and technologies of both electrophysiologists and cardiothoracic surgeons.

"The Convergent Procedure may set a new standard of care in AF ablation," said Kenneth C. Civello Jr., M.D., MPH, of Our Lady of the Lake Hospital, Baton Rouge, La. "This pioneering clinical study will evaluate the unmet need of the large persistent AF patient population for whom conventional endocardial ablation has been limited."

The multidisciplinary Convergent Procedure is performed as a single procedure in the electrophysiology lab. The epicardial component of the procedure is completed with no chest incisions, using the proprietary transdiaphragmatic approach that requires a 2 cm incision in the abdomen, providing the surgeon direct visualization to create lesions across the atrium.

"The convergent procedure is the least invasive option among multidisciplinary ablation techniques; there is no chest violation, no heart dissection, and no lung deflation," said Peter Walts, M.D., of St. Vincent Medical Group, Indianapolis, Ind. "By providing direct visualization and closed-chest access to the posterior left atrium, the convergent procedure may address major limitations experienced in traditional endocardial ablation."

The CONVERGE trial will randomize patients 2:1 between nContact's epicardial/endocardial convergent procedure using the EPi-Sense-AF
Guided Coagulation System with VisiTrax and standalone endocardial ablation using fluid-irrigated catheters for the treatment of persistent AF. The primary effectiveness endpoint is freedom from AF, atrial tachycardia, and atrial flutter without the use of new antiarrhythmic drugs. Secondary effectiveness endpoints include the reduction of AF burden and changes in Quality of Life measures from baseline: patients will be followed for 12 months post-procedure. Primary and secondary safety endpoints are the incidence of major adverse events following the initial procedure and through the 12-month follow-up period.

For more information: www.ncontactinc.com


Related Content

Acutus Medical, AcQMap High Resolution Imaging and Mapping System, improvement over sCT

Image courtesy of Acutus Medical

News | EP Mapping and Imaging Systems| October 06, 2015
Acutus Medical, a global heart rhythm technology company, presented data that show the AcQMap High Resolution Imaging...
News | Heart Failure| October 02, 2015
Cyberonics Inc. announced results from the extension of the ANTHEM-HF clinical study (ENCORE Study). Results of the...
AtriCure, cryoFORM cryoablation probe, launch
Technology | Ablation Systems| October 02, 2015
AtriCure Inc. launched the cryoFORM cryoablation probe, which offers increased probe flexibility to adapt to a variety...
predicting arrhythmias, mcgill university, alternans patterns
News | EP Lab| September 28, 2015
Researchers have discovered how to predict some cardiac arrhythmias several steps before they even occur. It’s a...
ACC, atrial fibrillation registries, ablation, left atrial appendage occlusion procedures, LAAO Registry
News | Atrial Fibrillation| September 24, 2015
The American College of Cardiology (ACC) launched two new clinical registry programs in August to track real-world...
Biotronik, NORDIC ICD trial, defibrillation testing, DF testing, shock efficacy
News | Implantable Cardioverter Defibrillators (ICD)| September 24, 2015
Biotronik announced the publication of NORDIC ICD (NO Regular Defibrillation testing In Cardioverter-Defibrillator...
guideline, treating supraventricular tachycardia, ACC, AHA, HRS
News | EP Lab| September 23, 2015
A new guideline aimed at helping clinicians treat patients with supraventricular tachycardia, or a rapid heart rate,...
MedLumics, OCT, real-time assessment, catheter ablation, atrial fibrillation
Feature | EP Mapping and Imaging Systems| September 17, 2015
MedLumics has announced the completion of a successful single-case pre-clinical feasibility study of its optical...
Texas Cardiac Arrhythmia Institute, TCAI, first in United States, EpiAccess System, epicardial ablation

Image courtesy of EpiEP

News | Ablation Systems| September 15, 2015
The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first facility in the...
Medtronic, Evera, ICD, MR-conditional, MRI, FDA approval
Technology | Implantable Cardioverter Defibrillators (ICD)| September 14, 2015
Medtronic received the first U.S. Food and Drug Administration (FDA) approval for an implantable cardioverter...
Overlay Init